Teva's ProAir HFA (albuterol sulfate inhalation aerosol) is now approved for the treatment and prevention of bronchospasm in children 4-11 years of age.

ProAir HFA has already been available for the treatment or prevention of bronchospasm in reversible obstructive airway disease and prevention of exercise-induced bronchospasm in patients ≥12 years of age.

For more information call (888) 482-9522 or visit www.ProAirHFA.com.